Open AccessContinued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
Author(s) -
Edahiro Ryuya,
Ishijima Mikako,
Kurebe Hiroyuki,
Nishida Kohei,
Uenami Takeshi,
Kanazu Masaki,
Akazawa Yuki,
Yano Yukihiro,
Mori Masahide
Publication year - 2019
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13065
Subject(s) - medicine , pembrolizumab , fulminant , adverse effect , type 1 diabetes , diabetes mellitus , diabetic ketoacidosis , adenocarcinoma , type 2 diabetes mellitus , insulin , gastroenterology , endocrinology , immunotherapy , cancer
A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently diagnosed with fulminant type 1 diabetes mellitus and ketoacidosis during the eighth course and insulin treatment was initiated. Pembrolizumab remained effective and was continued for 21 courses, even after the onset of diabetes mellitus. Immune‐checkpoint inhibitor treatment can be continued with hormone replacement even after the development of type 1 diabetes mellitus as an immune‐related adverse event.